Brokerages Set Twist Bioscience Corporation (NASDAQ:TWST) Target Price at $50.40

Twist Bioscience Corporation (NASDAQ:TWST - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the ten analysts that are covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have assigned a buy rating to the company. The average 12 month price objective among brokers that have covered the stock in the last year is $50.40.

A number of equities analysts have recently issued reports on the company. JPMorgan Chase & Co. dropped their target price on Twist Bioscience from $40.00 to $33.00 and set an "underweight" rating for the company in a report on Tuesday, May 6th. Robert W. Baird cut their price objective on Twist Bioscience from $54.00 to $44.00 and set an "outperform" rating for the company in a research report on Tuesday, May 6th. The Goldman Sachs Group cut their price target on Twist Bioscience from $55.00 to $48.00 and set a "buy" rating for the company in a report on Tuesday, May 6th. Guggenheim reissued a "buy" rating and issued a $50.00 price target on shares of Twist Bioscience in a report on Tuesday, May 6th. Finally, Barclays decreased their price target on Twist Bioscience from $58.00 to $45.00 and set an "overweight" rating on the stock in a report on Thursday, April 10th.

Insider Buying and Selling

In other news, insider Dennis Cho sold 689 shares of the firm's stock in a transaction dated Monday, May 5th. The stock was sold at an average price of $37.65, for a total transaction of $25,940.85. Following the sale, the insider owned 110,849 shares of the company's stock, valued at $4,173,464.85. This trade represents a 0.62% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Emily M. Leproust sold 5,042 shares of the business's stock in a transaction that occurred on Monday, May 5th. The shares were sold at an average price of $37.65, for a total value of $189,831.30. Following the completion of the transaction, the chief executive officer owned 655,432 shares of the company's stock, valued at $24,677,014.80. This represents a 0.76% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 21,911 shares of company stock worth $761,826 over the last ninety days. Insiders own 3.01% of the company's stock.

Institutional Trading of Twist Bioscience

Hedge funds have recently bought and sold shares of the stock. Versant Capital Management Inc increased its position in shares of Twist Bioscience by 547.2% during the first quarter. Versant Capital Management Inc now owns 686 shares of the company's stock worth $27,000 after acquiring an additional 580 shares in the last quarter. GAMMA Investing LLC lifted its position in Twist Bioscience by 68.1% in the 1st quarter. GAMMA Investing LLC now owns 748 shares of the company's stock valued at $29,000 after acquiring an additional 303 shares in the last quarter. Banque Transatlantique SA acquired a new position in Twist Bioscience in the 4th quarter worth $43,000. GF Fund Management CO. LTD. bought a new position in Twist Bioscience during the 4th quarter worth about $58,000. Finally, US Bancorp DE raised its stake in shares of Twist Bioscience by 72.0% in the 4th quarter. US Bancorp DE now owns 1,436 shares of the company's stock valued at $67,000 after purchasing an additional 601 shares during the period.

Twist Bioscience Stock Performance

Shares of NASDAQ:TWST traded up $0.93 during trading on Wednesday, hitting $37.68. 1,162,285 shares of the stock were exchanged, compared to its average volume of 964,158. The company has a market capitalization of $2.26 billion, a price-to-earnings ratio of -11.59 and a beta of 2.41. The company has a debt-to-equity ratio of 0.03, a quick ratio of 4.24 and a current ratio of 4.51. Twist Bioscience has a 1-year low of $27.12 and a 1-year high of $60.90. The company's fifty day simple moving average is $33.57 and its 200-day simple moving average is $40.38.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last posted its quarterly earnings results on Monday, May 5th. The company reported ($0.66) earnings per share for the quarter, missing analysts' consensus estimates of ($0.56) by ($0.10). Twist Bioscience had a negative return on equity of 33.48% and a negative net margin of 54.98%. The business had revenue of $92.79 million for the quarter, compared to analyst estimates of $92.00 million. Sell-side analysts expect that Twist Bioscience will post -2.12 EPS for the current fiscal year.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.